Clinical Trials | February 17, 2026
Teva and Sanofi duvakitug Phase 2b data show sustained efficacy in IBD
Duvakitug was well tolerated and safety was consistent with the induction study
Duvakitug was well tolerated and safety was consistent with the induction study
Findings to form the basis for a Phase 3 program, anticipated to start in H2 2025
The funding will be spread over four years, with BXLS also eligible for regulatory and commercial milestones, plus royalties on worldwide sales
Teva reported third quarter revenues of $4.5 billion, an increase of 3 per cent year-over-year.
Subscribe To Our Newsletter & Stay Updated
